In Plain English:
Syn-AKE is a lab-made three-amino-acid peptide developed in Basel, Switzerland by Pentapharm AG (now DSM-Firmenich). It copies the key functional region of Waglerin-1, a protein found in the venom of the Temple Viper (Tropidolaemus wagleri) that blocks nerve-to-muscle signalling. Applied topically, it competes with acetylcholine for the receptor slots on the muscle side of the neuromuscular junction — when it wins the slot, the ion channel stays shut, no sodium flows in, and the muscle cell stays relaxed. The result is a temporary softening of dynamic wrinkles (crow's feet, forehead lines, frown lines) — the kind caused by repeated facial movement rather than volume loss. In the primary manufacturer-sponsored human study, a 4% cream applied twice daily for 28 days reduced periorbital wrinkle depth by up to 52%, with measurable smoothing in 80% of the 50 volunteers. The mechanism is reversible and topical: unlike botulinum toxin it does not enter neurons, does not cleave SNARE proteins, and wears off within days of cessation. It is registered as a cosmetic active (INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate), sold by DSM-Firmenich as a preservative-free glycerin/water solution, used in formulations at 1–4%, and won Switzerland's Technology Award in 2006.
Research Maturity
Limited Human (~15 PubMed results for Syn-AKE; human efficacy data manufacturer-commissioned, no independent RCT replication+ Studies)
Focus
Aesthetic Dermatology
Cosmeceutical
Wrinkle Appearance
Origin
Developed by Pentapharm AG, Basel, Switzerland; research programme began ~1998; patent filed and ingredient announced 2001; first human trials 2002; EU cosmetic approval 2003; Swiss Technology Award 2006. DSM Nutritional Products acquired Pentapharm ~2012; subsequently rebranded as DSM-Firmenich upon the 2023 merger. Trade name: SYN-AKE®. INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate (also referred to as Tripeptide-3 in some older nomenclature). CAS: 823202-99-9 (diacetate salt, cosmetic-grade). PubChem CID: 71465152. FDA UNII: 38H206R00R. Structural inspiration: Waglerin-1, a 22-amino-acid paralytic peptide from Tropidolaemus wagleri venom; Syn-AKE is a 3-residue synthetic biomimetic of its nAChR-binding pharmacophore.
Mechanism
Competitive antagonist at the muscular nicotinic acetylcholine receptor (mnAChR) at the neuromuscular junction. The peptide (H-β-Ala-Pro-Dab-NH-Bzl) occupies the acetylcholine binding site on the α-subunit of the receptor. With the site blocked, the ligand-gated ion channel cannot open: Na⁺ influx is halted, the membrane does not depolarise, and the muscle fibre remains in a relaxed state. In vitro data report 71–82% reduction in contractile frequency in muscle cells at 0.025% within 1–2 hours, and up to 96.5% receptor blockade at 500 µM (IC₅₀ ≈ 180 µM in radioligand displacement assay). Crucially the antagonism is competitive and reversible — Syn-AKE does not enter the neuron or cleave any protein; full receptor activity returns on washout. Contrast botulinum toxin, which proteolytically cleaves SNAP-25 inside the presynaptic terminal. Secondary mechanisms identified by computational docking (Gok et al., 2023, PMID 37349941): stable binding to SIRT1 (longevity protein; docking score −9.32 kcal/mol) and matrix metalloproteinases MMP-13, MMP-8, MMP-1, suggesting potential collagen-protective activity beyond neuromuscular blockade; also concentration-dependent DPPH free-radical scavenging. These secondary data are entirely computational and in-vitro — no human confirmation.
Outcome
Primary human efficacy study (Pentapharm-sponsored, 50 volunteers, 28 days, twice-daily 4% SYN-AKE cream vs. placebo): up to 52% wrinkle depth reduction, measurable smoothing in 80% of participants, wrinkle reduction in 73% of participants; silicon imprint topography read-out. Cosmacon-cited 36-participant study (ages 35–60, ~0.2% concentration, 4 weeks): wrinkle depth reduced up to 25% with observable onset within 15 minutes of application. Quantified wrinkle-parameter study (n=100, split into 4 groups of 25, crow's feet, 4% cream, twice daily 28 days): 21% ± 9% overall size reduction at 3 weeks; 31.5% ± 9.2% size reduction at 6 weeks; 21% ± 9.2% depth reduction at 3 weeks; 30.1% ± 10.3% depth reduction at 6 weeks. Gorouhi & Maibach 2009 comparative review: Syn-AKE + leuphasyl combination achieved 24.62% combined wrinkle reduction vs. Argireline alone at 16.26%. In vitro mnAChR blockade (PMC11277145, 2024 reference assay): IC₅₀ ≈ 180 µM, 96.5% blockade at 500 µM. Gok et al. 2023 in silico + in vitro (PMID 37349941, J Biomol Struct Dyn): stable MMP and SIRT1 binding; DPPH antioxidant dose-response positive; negative Ames (genotoxicity) and MTT (cytotoxicity) at cosmetic concentrations.
